Table 3.
Summary of experiments assessing the level of cross protection to lethal RHDV infection provided by RCV-A1
| Study No. | Protection rate | N | RCV-A1 infection | Time post RCV-A1 infection | RHDV challenge | Reference |
|---|---|---|---|---|---|---|
| 1 |
52% |
11/21 |
Natural infection |
Unknown |
One dose 1000 LD 50, IM |
[14] |
| 2 |
36% |
22/61 |
Natural infection |
Unknown |
One dose 1500 LD 50, PO |
[15] |
| 3 |
33% |
25/77 |
Natural infection |
Unknown |
One dose 1500 LD 500, PO |
[29] |
| 4 |
50% |
2/4 |
Experimental infection |
4 weeks |
One dose 500 LD 50, PO |
[19] |
| 5a |
38% |
3/8 |
Natural infection |
< 8 weeks |
One dose 500 LD 50, PO and/or continuous exposure (contaminated environment) |
This report |
| 5b |
13% |
1/8 |
Natural infection |
8 - 10 weeks |
One dose 500 LD 50, PO and/or continuous exposure (contaminated environment) |
This report |
| 5c | 6% | 1/18 | Natural infection | > 10 weeks | One dose 500 LD 50, PO and/or continuous exposure (contaminated environment) | This report |
IM, Intra muscular, PO, Peroral.